Guggenheim Forecasts Strong Price Appreciation for InflaRx (NASDAQ:IFRX) Stock

InflaRx (NASDAQ:IFRX) had its price target boosted by equities research analysts at Guggenheim from $7.00 to $10.00 in a report issued on Wednesday, Marketbeat reports. The brokerage presently has a “buy” rating on the stock.

Separately, HC Wainwright reissued a “buy” rating and issued a $8.00 price target on shares of InflaRx in a report on Friday, March 21st.

InflaRx Price Performance

NASDAQ:IFRX opened at $1.25 on Wednesday. The firm has a market cap of $83.92 million, a price-to-earnings ratio of -1.16 and a beta of 1.98. The firm’s fifty day moving average price is $1.83 and its 200 day moving average price is $1.89. InflaRx has a 1-year low of $1.13 and a 1-year high of $2.82.

InflaRx (NASDAQ:IFRX) last issued its quarterly earnings data on Thursday, March 20th. The company reported ($0.09) EPS for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.18. InflaRx had a negative net margin of 33,362.70% and a negative return on equity of 65.98%. As a group, analysts expect that InflaRx will post -1.04 earnings per share for the current fiscal year.

Institutional Investors Weigh In On InflaRx

A number of hedge funds and other institutional investors have recently bought and sold shares of IFRX. Two Sigma Securities LLC acquired a new stake in shares of InflaRx in the 4th quarter valued at approximately $28,000. Walleye Capital LLC bought a new stake in InflaRx during the fourth quarter worth $51,000. Cubist Systematic Strategies LLC acquired a new stake in InflaRx in the fourth quarter valued at $55,000. Geode Capital Management LLC grew its position in shares of InflaRx by 32.8% in the 4th quarter. Geode Capital Management LLC now owns 48,136 shares of the company’s stock valued at $119,000 after acquiring an additional 11,900 shares during the period. Finally, Commonwealth Equity Services LLC increased its stake in shares of InflaRx by 20.5% during the 4th quarter. Commonwealth Equity Services LLC now owns 111,500 shares of the company’s stock worth $275,000 after purchasing an additional 19,000 shares during the last quarter. Institutional investors and hedge funds own 42.39% of the company’s stock.

InflaRx Company Profile

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.